Published in Curr Opin Urol on May 01, 2009
Risk stratification in prostate cancer screening. Nat Rev Urol (2012) 1.13
Aberrant PSA glycosylation--a sweet predictor of prostate cancer. Nat Rev Urol (2013) 1.03
Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers. Pharmacol Res (2010) 0.88
Tumour markers and kidney function: a systematic review. Biomed Res Int (2014) 0.85
A Review of Imaging Methods for Prostate Cancer Detection. Biomed Eng Comput Biol (2016) 0.79
The Role of Sarcosine, Uracil, and Kynurenic Acid Metabolism in Urine for Diagnosis and Progression Monitoring of Prostate Cancer. Metabolites (2017) 0.75
Predictors of pathological upgrading in low-risk prostate cancer patients without hypointense lesions on an apparent diffusion coefficient map of multiparametric magnetic resonance imaging. World J Urol (2016) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA (1995) 8.60
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
EAU guidelines on prostate cancer. Eur Urol (2007) 6.30
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst (2006) 6.02
Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol (1984) 5.36
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer (2008) 4.15
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol (2007) 3.72
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
Screening for prostate cancer. Cochrane Database Syst Rev (2006) 3.46
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA (1993) 3.46
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med (2006) 2.97
Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. JAMA (2003) 2.85
Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet (1994) 2.83
Active surveillance for prostate cancer: for whom? J Clin Oncol (2005) 2.70
Retracted EPCA-2: a highly specific serum marker for prostate cancer. Urology (2007) 2.67
PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol (2008) 2.63
Prostate-specific antigen levels as a predictor of lethal prostate cancer. J Natl Cancer Inst (2007) 2.49
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol (2008) 2.48
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. Eur Urol (2007) 2.40
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology (2001) 2.38
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Survival trends in European cancer patients diagnosed from 1988 to 1999. Eur J Cancer (2009) 2.12
Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology (2001) 2.10
Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries. J Natl Cancer Inst (2007) 2.08
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol (2008) 2.00
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol (2008) 1.91
Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection. Clin Chem (2008) 1.69
The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res (2007) 1.68
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer (2004) 1.63
Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol (2008) 1.58
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
POINT: EPCA-2: a promising new serum biomarker for prostatic carcinoma? Clin Biochem (2007) 1.56
Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology (2006) 1.51
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Biochemical recurrence after radical prostatectomy for prevalent versus incident cases of prostate cancer : implications for management. Cancer (2008) 1.46
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml. Eur Urol (2007) 1.45
Prostate-specific antigen in clinical practice. Cancer Lett (2007) 1.44
Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol (2005) 1.38
Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol (2005) 1.35
Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol (2008) 1.27
Predictors of subsequent prostate cancer in men with a prostate specific antigen of 2.6 to 4.0 ng/ml and an initially negative biopsy. J Urol (2005) 1.26
Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol (2008) 1.13
Prostate specific antigen assay standardization bias could affect clinical decision making. J Urol (2008) 1.12
Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med (2008) 1.12
Screening for prostate cancer: an update. Can J Urol (2008) 1.11
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007) 1.09
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. J Urol (2008) 1.05
Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. Ann Oncol (2007) 1.05
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer (2007) 1.04
Intermethod differences in results for total PSA, free PSA, and percentage of free PSA. Am J Clin Pathol (2008) 1.02
A meta-analysis of the performance characteristics of the free prostate-specific antigen test. Urology (2006) 0.99
Mass screening for prostate cancer in Korea: a population based study. J Urol (2008) 0.99
Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol (2004) 0.95
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem (2006) 0.95
Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Urol Oncol (2008) 0.94
Viewpoint: limiting prostate cancer screening. Ann Intern Med (2006) 0.94
Viewpoint: expanding prostate cancer screening. Ann Intern Med (2006) 0.91
Cutpoints in clinical chemistry: time for fundamental reassessment. Clin Chem (2008) 0.91
Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate (2005) 0.90
Standardization of PSA measures: a reappraisal and an experience with WHO calibration of Beckman Coulter Access Hybritech total and free PSA. Int J Biol Markers (2007) 0.89
Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial. Br J Cancer (2007) 0.89
Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol (2008) 0.88
Evaluation of serum and urinary myeloid related protein-14 as a marker for early detection of prostate cancer. J Urol (2008) 0.85
Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology (2007) 0.82
Biological aggressiveness of prostate cancer in the Finnish screening trial. Int J Cancer (2009) 0.81
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. Int J Cancer (2009) 0.81
Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging. J Urol (2008) 0.80
Clinical characteristics of prostate cancer in Japanese men in the eras before and after serum prostate-specific antigen testing. Int J Urol (2005) 0.79
Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen. Urology (2007) 0.78
Screening for prostate cancer among men 75 years of age or older. N Engl J Med (2008) 0.75
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol (2010) 12.64
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst (2011) 5.73
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. BMJ (2010) 4.42
Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest (2006) 4.37
Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. J Clin Oncol (2010) 4.15
Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol (2006) 4.05
Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol (2008) 4.02
Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst (2007) 3.70
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. BMJ (2014) 2.61
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. BMC Med (2008) 2.47
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med (2008) 2.39
Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. Eur Urol (2009) 2.31
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol (2012) 2.27
PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer (2007) 2.27
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? J Clin Oncol (2010) 2.26
Prostate cancer mortality in areas with high and low prostate cancer incidence. J Natl Cancer Inst (2014) 2.16
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. Eur Urol (2011) 2.14
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem (2005) 2.05
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol (2009) 2.05
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am J Hum Genet (2005) 1.96
Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. Eur Urol (2006) 1.94
Lead time associated with screening for prostate cancer. Int J Cancer (2004) 1.93
Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov (2012) 1.87
Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86
Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. Eur Urol (2011) 1.85
Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments. Anal Chem (2006) 1.84
Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol (2012) 1.82
Prostate cancer: estimating the benefits of PSA screening. Nat Rev Urol (2009) 1.76
Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst (2003) 1.73
Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res (2009) 1.68
Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer (2004) 1.63
Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Arch Intern Med (2005) 1.57
Systematic review of statistical methods used in molecular marker studies in cancer. Cancer (2008) 1.53
Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. J Urol (2003) 1.49
A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. Biochem J (2002) 1.47
Standardization of two immunoassays for human glandular kallikrein 2. Clin Chem (2003) 1.45
Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst (2004) 1.44
Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2011) 1.42
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk? BJU Int (2013) 1.39
Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. Clin Cancer Res (2007) 1.38
Translational crossroads for biomarkers. Clin Cancer Res (2005) 1.38
Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. Cancer Prev Res (Phila) (2010) 1.35
Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. Prostate (2009) 1.33
miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer (2010) 1.32
Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer (2009) 1.32
Tumor markers in prostate cancer I: blood-based markers. Acta Oncol (2011) 1.28
Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol (2005) 1.28
Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis. Anal Chem (2012) 1.26
A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res (2010) 1.24
Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. Clin Cancer Res (2002) 1.23
Susceptibility loci associated with prostate cancer progression and mortality. Clin Cancer Res (2010) 1.19
Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. Cancer Epidemiol Biomarkers Prev (2010) 1.18
Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem (2004) 1.15
The evolution of a genetic locus encoding small serine proteinase inhibitors. Biochem Biophys Res Commun (2005) 1.14
Prostate kallikrein markers in diagnosis, risk stratification and prognosis. Nat Rev Urol (2009) 1.13
Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics. Anal Chem (2009) 1.13
A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev (2010) 1.12
A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem (2006) 1.12
Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. Cancer Epidemiol Biomarkers Prev (2010) 1.12
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. BMC Med (2014) 1.11
Screening for prostate cancer: an update. Can J Urol (2008) 1.11
Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer (2007) 1.09
beta-Microseminoprotein binds CRISP-3 in human seminal plasma. Biochem Biophys Res Commun (2005) 1.07
Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol (2004) 1.06
Recovery of urinary function after radical prostatectomy: predictors of urinary function on preoperative prostate magnetic resonance imaging. J Urol (2012) 1.05
Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate (2006) 1.04
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer (2007) 1.04
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. BMC Cancer (2010) 1.03
Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol Suppl (2005) 1.03
The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS One (2010) 1.01
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World J Urol (2011) 1.00
Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res (2003) 1.00
Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol (2016) 1.00
Increase in percent free prostate-specific antigen in men with chronic kidney disease. Nephrol Dial Transplant (2008) 1.00
Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males. J Androl (2008) 0.99
Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. Nephron Physiol (2003) 0.98
Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem (2006) 0.95
Ethnic variation in pelvimetric measures and its impact on positive surgical margins at radical prostatectomy. Urology (2010) 0.94
Integrated selective enrichment target--a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases. Electrophoresis (2004) 0.94
Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. J Proteomics (2010) 0.94
Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol (2012) 0.94
A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations. Cancer Epidemiol Biomarkers Prev (2010) 0.94